Cancer/testis antigen 1 (95-107)

Cancer/testis antigen 1 (95-107) is a synthetic peptide segment derived from the well-characterized cancer/testis antigen family, recognized for its restricted expression in germ cells and a wide range of tumor types. As a defined peptide epitope corresponding to amino acids 95 through 107, it serves as a valuable molecular tool for investigating antigen-specific immune responses, peptide-MHC interactions, and the mechanisms underlying tumor immunogenicity. Its unique sequence and immunological relevance make it a significant resource in the fields of cancer biology, immunology, and peptide-based assay development.

Epitope mapping: Researchers employ this peptide to delineate T cell epitopes within the cancer/testis antigen 1 protein, facilitating the identification of immunodominant regions recognized by cytotoxic T lymphocytes. By using it in binding and stimulation assays, investigators can clarify which segments of the parent protein are most potent in eliciting immune responses. Such mapping is crucial for understanding antigen presentation and for guiding the rational design of immunotherapeutic strategies targeting tumor-associated antigens.

Immunogenicity assessment: The peptide is widely utilized in studies aimed at evaluating the immunogenic properties of cancer/testis antigens in both in vitro and ex vivo settings. By incorporating the 95-107 sequence into ELISPOT, intracellular cytokine staining, or proliferation assays, scientists can monitor antigen-specific T cell activation and cytokine production. These applications provide critical insights into the immune system's capacity to recognize and respond to tumor-associated peptide epitopes, supporting the development of novel immunotherapeutic approaches.

Peptide-MHC binding studies: As a defined linear epitope, the 95-107 fragment is instrumental in exploring its affinity and stability within major histocompatibility complex (MHC) molecules. Researchers use this peptide to assess MHC class I binding preferences, inform computational prediction models, and validate peptide presentation on the surface of antigen-presenting cells. Such studies enhance the understanding of antigen processing and the parameters influencing effective immune surveillance against tumor cells.

Development of peptide-based assays: The defined sequence and immunological relevance of this peptide make it a preferred standard in the development and validation of immunoassays, including peptide-MHC tetramer staining and T cell receptor (TCR) specificity testing. By serving as a control or experimental antigen, it enables consistent quantification of antigen-specific T cell populations, thus supporting high-throughput screening and immune monitoring in preclinical research.

Peptide synthesis and modification research: The Cancer/testis antigen 1 (95-107) peptide also finds application in studies focused on optimizing peptide synthesis protocols and evaluating the impact of sequence modifications on stability, solubility, and immunogenicity. Researchers may employ this fragment as a model system to develop new conjugation strategies, improve peptide delivery methods, or investigate the role of specific amino acid substitutions in modulating biological activity. These efforts contribute to the advancement of peptide chemistry and the refinement of synthetic approaches for research and biotechnological applications.

1. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

2. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

3. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

4. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry

5. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury